Acesso livre
Acesso livre

Covid-19 (Temas de Saúde Pública)

Pílula da Pfizer contra COVID deve ser fabricada e vendida mais barata em 95 países pobres.

17 Nov, 2021 | 13:03h

Pfizer COVID Pill to Be Made, Sold Cheaply in 95 Poor Countries – HealthDay

Ver também:

Pfizer agrees to license generic versions of its COVID-19 pill — in some countries – NPR

Pfizer and Medicines Patent Pool Reach ‘Ground-breaking’ Voluntary Licensing Deal for New COVID-19 Treatment Pill – Health Policy Watch

Pfizer Will Allow Its Covid Pill to Be Made and Sold Cheaply in Poor Countries – The New York Times (poucos artigos gratuitos por mês)

MSF responde à licença da Pfizer e do Medicines Patent Pool para o novo tratamento da Covid-19 – “O acordo, porém, cobre somente 53% da população mundial e exclui pessoas em diversos países de média renda, deixando esse medicamento promissor fora do alcance de milhões de pessoas.”

17 Nov, 2021 | 13:01h

MSF responds to Pfizer and Medicines Patent Pool license for new Covid-19 treatment – Médecins Sans Frontières

 

Comentário no Twitter

 

Covid: Áustria impõe lockdown a não vacinados.

16 Nov, 2021 | 12:44h

Covid: Austria introduces lockdown for unvaccinated – BBC

Ver também: Austria orders nationwide lockdown for the unvaccinated – Associated Press

Covid-19: produção global de vacinas é desordenada e a escassez é decorrente de outros fatores além da acumulação por alguns países.

16 Nov, 2021 | 12:43h

Covid-19: global vaccine production is a mess and shortages are down to more than just hoarding – The BMJ

 

Comentário no Twitter

 

Pílula da Pfizer é o mais recente tratamento contra COVID a se mostrar promissor.

16 Nov, 2021 | 12:41h

Pfizer’s pill is the latest COVID treatment to show promise. Here are some more – The Conversation

Conteúdos relacionados:

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Estudo randomizado fase 4 | Administração de vacinas contra COVID-19 (AstraZeneca ou Pfizer) concomitantemente às vacinas contra influenza sazonal em adultos é segura e preserva a resposta imune de ambas as vacinas.

15 Nov, 2021 | 14:10h

Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial – The Lancet

Amplo estudo populacional mostra que infecção prévia por SARS-CoV-2 reduz o risco de infecção após vacina de mRNA.

15 Nov, 2021 | 14:08h

Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar – JAMA

Comentários:

Vaccine plus previous infection may offer enhanced COVID-19 protection – CIDRAP

Prior SARS-CoV-2 infection and risk of breakthrough infection following mRNA vaccination – News Medical

 

Comentário no Twitter

 

Estudo populacional no Catar mostrou que a efetividade contra doença grave, crítica ou fatal induzida pela variante Delta do SARS-CoV-2 foi de 93,4% para a vacina da Pfizer e de 96,1% para a vacina da Moderna.

15 Nov, 2021 | 14:06h

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar – Nature Medicine

 

Comentário no Twitter

 

[Preprint] Risco de COVID-19 grave é raro entre pessoas com vacinação plena na Inglaterra.

15 Nov, 2021 | 14:01h

Comentário: Risk of severe COVID-19 is rare among fully vaccinated individuals in England – News Medical

Estudo original: Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: A cohort study from OpenSAFELY – medRxiv

Editorial | COVID está conturbando carreiras científicas pelo mundo.

15 Nov, 2021 | 13:59h

COVID is disrupting scientific careers around the world – Nature

Ver também:

Scientists count the career costs of COVID – Nature

Potentially long-lasting effects of the pandemic on scientists – Nature

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.